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Introduction {#jdi12586-sec-0005}
============

Type 1 diabetes mellitus is a multifactorial disease in which pancreatic β‐cells are destroyed primarily by a T cell‐mediated autoimmune reaction[1](#jdi12586-bib-0001){ref-type="ref"}. Autoimmunity in type 1 diabetes is facilitated by various cells, including dendritic cells (DCs)[1](#jdi12586-bib-0001){ref-type="ref"}, [2](#jdi12586-bib-0002){ref-type="ref"}, [3](#jdi12586-bib-0003){ref-type="ref"}. A subset of patients with type 1 diabetes shows familial aggregation, suggesting a significant contribution of genetic factors to the etiology of the disease[1](#jdi12586-bib-0001){ref-type="ref"}. Type 1 diabetes represents a polygenic disorder, whereas other forms of diabetes mellitus, such as maturity‐onset diabetes of the young, neonatal diabetes and syndromic diabetes, often result from monogenic mutations or chromosomal abnormalities[1](#jdi12586-bib-0001){ref-type="ref"}, [2](#jdi12586-bib-0002){ref-type="ref"}. Genome‐wide association studies (GWAS), together with candidate gene approaches, have identified more than 50 susceptibility genes for type 1 diabetes[2](#jdi12586-bib-0002){ref-type="ref"}. However, these genes account for just \~80% of the genetic heritability of type 1 diabetes, indicating that additional disease‐associated genes remain to be identified[2](#jdi12586-bib-0002){ref-type="ref"}, [4](#jdi12586-bib-0004){ref-type="ref"}. In particular, susceptibility variants of low frequency might be undetected by GWAS, as this method focuses primarily on relatively common polymorphisms[5](#jdi12586-bib-0005){ref-type="ref"}.

CD101 (also known as V7 and IGSF2) is a transmembrane glycoprotein expressed on various types of immune cells[6](#jdi12586-bib-0006){ref-type="ref"}, [7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}, [9](#jdi12586-bib-0009){ref-type="ref"}. *Cd101* has been reported as an 'autoimmune diabetes gene in the non‐obese diabetic (NOD) mouse'[10](#jdi12586-bib-0010){ref-type="ref"}, [11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}. Murine CD101 is known to modulate the function of regulatory T cells and antigen‐presenting cells, with genotype‐dependent *Cd101* expression determining the risk of autoimmune diabetes in NOD mice[11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}. In addition, monoclonal antibodies against CD101 inhibit allogeneic T cell responses[9](#jdi12586-bib-0009){ref-type="ref"}. Human CD101 has also been implicated in immune regulation[7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}, [13](#jdi12586-bib-0013){ref-type="ref"}, [14](#jdi12586-bib-0014){ref-type="ref"}, [15](#jdi12586-bib-0015){ref-type="ref"}, [16](#jdi12586-bib-0016){ref-type="ref"}. Previous studies have suggested that human CD101 plays a costimulatory role in T cell activation mediated by T cell receptor/CD3 or skin DCs[7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}. However, *CD101* mutations have not been associated with diabetes in humans. Here, we report the identification of three *CD101* substitutions in patients with type 1 diabetes. These substitutions were detected through whole‐exome sequencing of familial cases and mutation screening of sporadic cases.

Materials and Methods {#jdi12586-sec-0006}
=====================

Whole‐exome sequencing and genome‐wide copy‐number analysis of a family with type 1 diabetes {#jdi12586-sec-0007}
--------------------------------------------------------------------------------------------

The present study was approved by the institutional review board committee at the National Center for Child Health and Development, and was carried out after obtaining written informed consent. We carried out molecular analyses of a Japanese family (family A) consisting of two patients with type 1 diabetes and three unaffected relatives. The male proband (case 1) and his mother (case 2) developed diabetes at the ages 2.6 and 18 years, respectively (Table [1](#jdi12586-tbl-0001){ref-type="table-wrap"}). At disease onset, case 1 was positive for the insulin autoantibody, whereas case 2 was positive for the islet cell surface antibody. Human leukocyte antigen (*HLA*) typing showed known risk alleles of the Japanese population[17](#jdi12586-bib-0017){ref-type="ref"}, *DRB1\*04:05* and *DQB1\*04:01*, in cases 1 and 2 and two unaffected family members, and *DQB1\*03:02* in case 1 and his unaffected father (Table [1](#jdi12586-tbl-0001){ref-type="table-wrap"}). The unaffected grandmother of case 1 (the mother of case 2) carried two risk alleles, *DRB1\*04:05* and *DQB1\*04:01*, together with a protective *DQB1\*03:01* allele. Cases 1 and 2 showed no additional clinical features. No family history of other autoimmune diseases was recorded in this family.

###### 

Clinical and molecular findings of *CD101*‐substitution‐positive patients and unaffected family members

  Familial/Sporadic                               Family A              Sporadic                                                          Sporadic                                                                                                                       
  ----------------------------------------------- --------------------- ----------------------------------------------------------------- -------------------------------------------------- ----------------- ----------------- ----------------- --------------------- ---------------------
  Sex                                             Male                  Female                                                            Female                                             Male              Male              Female            Male                  Female
  Clinical findings at the onset of the disease                                                                                                                                                                                                                          
  Age at onset (years)                            2.6                   18                                                                --                                                 --                --                --                10.5                  13.2
  Body mass index (kg/m^2^)                       14.8 (14.4--17.2)     22 (16.3--23.5)                                                   --                                                 --                --                --                17.1 (15.0--21.5)     16.6 (16.3--23.5)
  Blood glucose (mmol/L)                          **18.9** (4.1--5.2)   **8.6** (4.4--5.2)                                                --                                                 --                --                --                **51** (4.5--5.2)     **13** (4.4--5.2)
  HbA1c (mmol/mol)                                **95** (26--36)       **53** (26--36)                                                   --                                                 --                --                --                **89** (26--36)       **92** (26--36)
  HbA1c (%)                                       **10.8** (4.5--5.4)   **7** (4.5--5.4)                                                  --                                                 --                --                --                **10.3** (4.5--5.4)   **10.6** (4.5--5.4)
  Blood C‐peptide (nmol/L)                        **0.2** (0.3--0.6)    NA                                                                --                                                 --                --                --                **0.2** (0.4--0.8)    NA
  Urine C‐peptide (μg/day)                        **\<9** (12--34)      **15** (29--167)                                                  --                                                 --                --                --                NA                    90 (29--167)
  Anti‐GAD antibody (U/mL)                        Negative (\<1.5)      NA                                                                --                                                 --                --                --                **3.8** (\<1.5)       **81** (\<1.5)
  Insulin autoantibody (%)                        **20.8** (\<10)       NA                                                                --                                                 --                --                --                NA                    NA
  Islet cell surface antibody                     NA                    **Positive** [†](#jdi12586-note-0001){ref-type="fn"} (negative)   --                                                 --                --                --                NA                    NA
  Molecular findings                                                                                                                                                                                                                                                     
  *HLA‐DRB1*                                      [*\*4:05*]{.ul}       [*\*4:05*]{.ul}                                                   [*\*4:05*]{.ul}                                    *\*11:01*         [*\*4:05*]{.ul}   [*\*4:05*]{.ul}   [*\*4:05*]{.ul}       [*\*9:01*]{.ul}
  *\*11:01*                                       [*\*4:05*]{.ul}       *\*12:02*                                                         *\*13:02*                                          *\*13:02*         *\*13:02*         [*\*9:01*]{.ul}   [*\*9:01*]{.ul}       
  *HLA‐DQB1*                                      [*\*3:02*]{.ul}       [*\*4:01*]{.ul}                                                   *\*3:01* [‡](#jdi12586-note-0001){ref-type="fn"}   [*\*3:02*]{.ul}   [*\*4:01*]{.ul}   [*\*4:01*]{.ul}   [*\*3:03*]{.ul}       [*\*3:03*]{.ul}
  [*\*4:01*]{.ul}                                 [*\*4:01*]{.ul}       [*\*4:01*]{.ul}                                                   *\*6:09*                                           *\*6:09*          *\*6:09*          [*\*4:01*]{.ul}   [*\*3:03*]{.ul}       
  *CD101* substitution                            p.V863L               p.V863L                                                           p.V863L                                            None              None              None              p.V678L               p.T944R

Reference ranges are shown in parentheses. Values above or below the reference range are boldfaced. Glycated hemoglobin (HbA1c) is measured by a National Glycohemoglobin Standardization Program‐certified method (%), and converted to International Federation of Clinical Chemistry value (mmol/mol). Human leukocyte antigen (HLA) class II genotypes known as risk alleles of diabetes in Japanese are underlined. ^†^Actual value unknown. ^‡^Known as a protective allele of diabetes in Japanese. NA, not analyzed.
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We carried out whole‐exome sequencing using genomic DNA samples obtained from cases 1 and 2 and three unaffected family members (the father and two older siblings of the proband). DNA libraries were constructed using a SureSelect Kit (51 Mb version 4; Agilent Technologies, Santa Clara, CA, USA), and sequenced using a Hiseq 1000 sequencer (Illumina, San Diego, CA, USA). Nucleotide alterations were called by Avadis NGS 1.3.1 (DNA Chip Research, Yokohama, Japan) or SAMtools 0.1.17 software (<https://sourceforge.net/projects/samtools/files/samtools/>). We searched for nucleotide alterations shared by cases 1 and 2, but absent from the three unaffected relatives. We focused on exonic mutations that alter protein sequences and intronic substitutions located within a 5‐bp region from an exon--intron boundary. Known polymorphisms with an allele frequency of more than 1.0% in the general population (NCBI Browser, <http://www.ncbi.nlm.nih.gov/>), and mutations whose functional outcomes were predicted as 'benign' by *in silico* analysis using PolyPhen‐2 (<http://genetics.bwh.harvard.edu/pph2/>) were excluded from further analysis. We referred to the OMIM database (<https://www.ncbi.nlm.nih.gov/omim>) to examine whether the genes identified in the present study were associated with any human disorders. We also searched the PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed/>) for previous reports on these genes. Nucleotide alterations in *CD101* (NM_004258) and *GAD2* (NM_000818.2) were confirmed by Sanger sequencing. Primer sequences are available on request. In addition, we analyzed the parental origin of a *CD101* mutation identified in case 2. Copy‐number alterations in case 1 were analyzed by array‐based comparative genomic hybridization (SurePrint G3 Human Microarray, 2 × 400 k format; Agilent Technologies). We referred to the Database of Genomic Variants (<http://projects.tcag.ca/variation/>) to exclude known benign variants.

Mutation screening of *CD101* in sporadic cases with type 1 diabetes {#jdi12586-sec-0008}
--------------------------------------------------------------------

We carried out mutation screening of *CD101* in 127 sporadic cases with type 1 diabetes (49 males and 78 females, aged 2.0--18.1 years). All patients were of Japanese origin, and developed diabetes between the age of 0.9 and 15.7 years. The patients were positive for anti‐GAD and/or islet antigen 2 antibodies. Patients with syndromic diabetes were excluded from the study.

Nucleotide alterations in *CD101* coding exons and their flanking regions were examined by amplicon‐sequencing using Nextera Kits (FC‐121‐1031 and FC‐121‐1012; Agilent Technologies) and a Miseq next‐generation sequencer (Illumina). All *CD101* nucleotide alterations, except for common polymorphisms found in the NCBI Browser, were confirmed by Sanger sequencing. To assess the presence or absence of the pathogenicity of *CD101* substitutions, we attempted to obtain parental samples of mutation‐positive patients.

Functional assessment of *CD101* substitutions {#jdi12586-sec-0009}
----------------------------------------------

We examined whether the *CD101* substitutions identified in the patients are present in the general population. First, we analyzed 185 DNA samples obtained from healthy Japanese controls (Human Science Research Resources Bank, Tokyo, Japan; present distributer, National Institute of Biomedical Innovation, Osaka, Japan). The presence or absence of the *CD101* substitutions were examined by single‐nucleotide polymorphism genotyping (custom‐made TaqMan SNP Genotyping Assays; Life Technologies, Carlsbad, CA, USA) or by Sanger direct sequencing. Second, we examined frequencies of the *CD101* substitutions in databases. We referred to the Human Genetic Variation Database (<http://www.genome.med.kyoto-u.ac.jp/SnpDB/>) and the Exome Aggregation Consortium (ExAC) Browser (<http://exac.broadinstitute.org/>). We also examined the position and evolutionary conservation of affected amino acids in the CD101 protein.

Expression analysis of CD101 in unaffected individuals and substitution‐positive patients {#jdi12586-sec-0010}
-----------------------------------------------------------------------------------------

To analyze CD101 expression on hematopoietic cells, we carried out multicolor fluorescence‐activated cell sorting using LSRFortessa (BD Biosciences, San Jose, CA, USA). Fresh peripheral blood was obtained from five healthy individuals and three *CD101* substitution‐positive patients (cases 1, 2 and 4). Fresh blood samples of case 3 were unavailable. Populations of lymphocytes, monocytes and granulocytes were differentiated using forward scatter and side scatter of flow cytometry. For analysis of CD101 expression on DCs, cells expressing human CD45 were gated on HLA‐DR^+^ and lineage^−^, and divided into two subpopulations in terms of expression of CD11c and CD123; that is, CD11c^+^/CD123^−^ cells and CD11c^−^/CD123^+^ cells, which were referred to as myeloid and plasmacytoid DCs, respectively (Figure [1](#jdi12586-fig-0001){ref-type="fig"}a,b). Antibodies used were FITC‐conjugated human CD45, APC‐Cy7‐conjugated HLA‐DR, APC‐conjugated CD123, PerCP‐Cy5.5‐conjugated CD11c, PE‐conjugated CD101, and brilliant violet 421‐conjugated CD3, CD19 and CD14 for lineage markers. The CD101 antibody was purchased from AbD Serotec (Kidlington, Oxford, UK), and other antibodies were purchased from BioLegend (San Diego, CA, USA).

![CD101 expression on peripheral blood cells. (a) Major subpopulations of peripheral blood cells, such as lymphocytes (Lymp), monocytes (Mono) and neutrophils (Neutro), were differentiated based on forward scatter (FSC)/side scatter (SSC) of flow cytometry. (b) Cells expressing human CD45 were gated on human leukocyte antigen‐DR positive (HLA‐DR^+^) and lineage^−^, and divided into two subpopulations; that is, CD11c^+^/CD123^−^ myeloid dendritic cells (mDCs) and CD11c^−^/CD123^+^ plasmacytoid DCs (pDCs). (c) Results of cases 1, 2 and 4 are shown in blue lines. Representative results of control individuals and the unstained control population of cells are shown with red and gray lines, respectively. Samples of case 3 were not available for this analysis.](JDI-8-286-g001){#jdi12586-fig-0001}

Results {#jdi12586-sec-0011}
=======

Molecular analyses of family A {#jdi12586-sec-0012}
------------------------------

Whole‐exome sequencing of family A showed that nine hitherto unreported nucleotide changes in nine genes and 15 rare polymorphisms in 14 genes co‐segregated with type 1 diabetes (Table [2](#jdi12586-tbl-0002){ref-type="table-wrap"}; Figure [2](#jdi12586-fig-0002){ref-type="fig"}a,b). Seven of the 24 nucleotide changes were intronic substitutions or an inframe insertion of unknown pathogenicity. Of the 23 mutated genes, *CD101* represented the human homolog of a known diabetes‐causative gene in NOD mice[11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}, and *GAD2* encoded a major autoantigen for type 1 diabetes[3](#jdi12586-bib-0003){ref-type="ref"}. The p.V863L substitution in *CD101* was hitherto unreported, whereas the p.I228T substitution in *GAD2* was found in 262 of 121,380 alleles in the ExAC Browser. The remaining 21 genes have not been associated with type 1 diabetes or other autoimmune disorders; eight of these genes were associated with some genetic disorders other than diabetes. The p.V863L substitution in *CD101* was shared by the unaffected mother of case 2 (the grandmother of case 1). Mutations in known diabetes‐associated genes, including *INS*,*PTPN22*,*IL2RA* and *CTLA4*, were not found in this family. Genome‐wide copy‐number analysis in case 1 detected no deletions or duplications, except for common copy‐number variations.

###### 

Nucleotide substitutions identified by whole‐exome sequencing of family A

  Gene                                               Nucleotide change   Amino acid change   Allele frequency in the general population   *In silico* functional prediction[‡](#jdi12586-note-0002){ref-type="fn"}   Human disease associated with the gene[§](#jdi12586-note-0002){ref-type="fn"}   
  -------------------------------------------------- ------------------- ------------------- -------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------
  Rare polymorphism                                                                                                                                                                                                                                                                                  
  *COL3A1* [†](#jdi12586-note-0002){ref-type="fn"}   IVS25 + 5           --                  0.004                                        74/121,400                                                                 Unknown                                                                         Ehlers--Danlos syndrome
  *NEDD4L*                                           IVS14 + 5           --                  0.002                                        13/103,616                                                                 Unknown                                                                         Unknown
  *GK*                                               IVS17 + 4           --                  0.008                                        0                                                                          Unknown                                                                         Glycerol kinase deficiency
  *SMARCAD1*                                         IVS1‐2              --                  0                                            1/119,520                                                                  Unknown                                                                         Adermatoglyphia
  *GAD2*                                             T683C               I228T               0.005                                        262/121,380                                                                Possibly damaging                                                               Unknown
  *COL3A1* [†](#jdi12586-note-0002){ref-type="fn"}   G3133A              A1045T              0.003                                        71/121,296                                                                 Probably damaging                                                               Ehlers--Danlos syndrome
  *OR52D1*                                           G604A               G202R               0.004                                        878/121,376                                                                Probably damaging                                                               Unknown
  *OBSCN*                                            T8774G              L2925R              0.002                                        6/119,982                                                                  Probably damaging                                                               Unknown
  *LYST*                                             T9898C              Y3299C              0.002                                        3/21,498                                                                   Probably damaging                                                               Chediak--Higashi syndrome
  *VCPIP1*                                           G2513C              P837A               0.001                                        0                                                                          Probably damaging                                                               Unknown
  *MYF5*                                             A431G               N144S               0.001                                        0                                                                          Possibly damaging                                                               Unknown
  *ZNF469*                                           C7381T              R2461W              0.001                                        0                                                                          Probably damaging                                                               Brittle cornea syndrome
  *FOXS1*                                            G878C               P292A               0.007                                        15/118,480                                                                 Possibly damaging                                                               Unknown
  *C1QTNF8*                                          C140T               D46N                0.001                                        1/109,732                                                                  Possibly damaging                                                               Unknown
  *PDE11A*                                           G481C               S160X               0.002                                        0                                                                          No data                                                                         Pigmented nodular adrenocortical disease
  *CREB3L1*                                          IVS11 + 1           --                  0                                            0                                                                          Unknown                                                                         Unknown
  *GOLGA8S*                                          IVS16‐5             --                  0                                            0                                                                          Unknown                                                                         Unknown
  *TPRN*                                             1650insCCG          550_551insA         0                                            0                                                                          Unknown                                                                         Hearing loss
  *CD101*                                            G2587T              V863L               0                                            0                                                                          Possibly damaging                                                               Unknown
  *PREX2*                                            T2699C              I900T               0                                            0                                                                          Possibly damaging                                                               Oncogene
  *LOH12CR1*                                         G451C               E151Q               0                                            0                                                                          Probably damaging                                                               Unknown
  *ZNF532*                                           C449G               P150R               0                                            0                                                                          Probably damaging                                                               Unknown
  *SDF2L1*                                           C185A               S62Y                0                                            0                                                                          Probably damaging                                                               Unknown
  *SHROOM2*                                          C3890T              S1297F              0                                            0                                                                          Probably damaging                                                               Ocular albinism

ExAC, the Exome Aggregation Consortium Browser; HGVD, Human Genetic Variation Database. ^†^Two polymorphisms were identified in *COL3A1*. ^‡^Based on the data of PolyPhen‐2 (<http://genetics.bwh.harvard.edu/pph2/>). ^§^Based on the data of OMIM (<http://www.ncbi.nlm.nih.gov/omim>).
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![Nucleotide substitutions of *CD101* identified in the present study. (a) The structure of wild‐type *CD101* DNA and CD101 protein, and the position of three substitutions. The black and white boxes on genomic deoxyribonucleic acid denote the coding regions and the untranslated regions, respectively. The p.V678L and p.V863L substitutions resided within the immunoglobulin‐like domains (blue boxes), while the p.T944R substitution was located in a connecting region between an immunoglobulin‐like domain and the transmembrane domain (orange box). The signal peptide (red box) was not affected by these substitutions. (b) Three substitutions in *CD101*. These substitutions were identified by next‐generation sequencing and confirmed by Sanger sequencing (left panel). The black arrows indicate mutated nucleotides. Representative results of an *in silico* analysis (PolyPhen‐2) are shown (middle panel). Evolutionary conservation of each substitution is shown (right panel).](JDI-8-286-g002){#jdi12586-fig-0002}

Mutation screening of *CD101* in sporadic cases with type 1 diabetes {#jdi12586-sec-0013}
--------------------------------------------------------------------

Mutation screening of *CD101* of 127 sporadic patients identified 10 rare nucleotide substitutions (Table S1). These substitutions included p.V678L and p.T944R, which were absent or extremely rare in the general populations, and were assessed as 'probably damaging' by *in silico* analysis (Table S1; Figure [2](#jdi12586-fig-0002){ref-type="fig"}a,b). Case 3 carrying the p.V678L substitutions and case 4 carrying the p.T944R substitutions developed diabetes at 10.5 and 13.2 years‐of‐age, respectively (Table [1](#jdi12586-tbl-0001){ref-type="table-wrap"}). At disease onset, these cases were positive for anti‐GAD antibodies. Both cases 3 and 4 carried risk *HLA* alleles of the Japanese population. Blood samples from family members of cases 3 and 4 were unavailable for genetic testing.

Functional assessment of *CD101* substitutions {#jdi12586-sec-0014}
----------------------------------------------

The p.V863L, p.V678L and p.T944R substitutions were absent in 185 healthy Japanese individuals. Furthermore, these substitutions have not been registered in the Human Genetic Variation Database. Likewise, the p.V678L and p.V863L substitutions were absent from 121,412 alleles in the ExAC Browser, and the p.T944R substitution has been identified in one of 121,370 alleles.

The p.V678L and p.V863L substitutions resided within the immunoglobulin‐like domains of CD101, whereas the p.T944R substitution was located in a connecting region between an immunoglobulin‐like domain and the transmembrane domain (Figure [2](#jdi12586-fig-0002){ref-type="fig"}a). The signal peptide was not affected by these substitutions. The three substitutions involved nucleotides that were evolutionary conserved among humans, rhesus, dogs and elephants (Figure [2](#jdi12586-fig-0002){ref-type="fig"}b).

Expression analysis of CD101 in unaffected individuals and substitution‐positive patients {#jdi12586-sec-0015}
-----------------------------------------------------------------------------------------

In keeping with previous reports[7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}, [9](#jdi12586-bib-0009){ref-type="ref"}, [13](#jdi12586-bib-0013){ref-type="ref"}, [14](#jdi12586-bib-0014){ref-type="ref"}, CD101 was highly expressed on monocytes and granulocytes of control individuals, whereas lymphocytes including T cells, B cells and natural killer cells of these individuals barely expressed it (red lines in Figure [1](#jdi12586-fig-0001){ref-type="fig"}c). Interestingly, the expression of CD101 on the monocytes and granulocytes of cases 1, 2 and 4 was weaker than that of the control individuals. The reduction of CD101 expression was also observed in myeloid DCs of these cases (Figure [1](#jdi12586-fig-0001){ref-type="fig"}b and blue lines in Figure [1](#jdi12586-fig-0001){ref-type="fig"}c). Expression of CD101 was weak or absent on plasmacytoid DCs of both patients and control individuals. Collectively, the *CD101* mutations likely affected protein expression primarily on myeloid lineage cells.

Discussion {#jdi12586-sec-0016}
==========

Whole‐exome sequencing of family A showed that a p.V863L substitution in *CD101*, the human homolog of an autoimmune diabetes gene in NOD mice[10](#jdi12586-bib-0010){ref-type="ref"}, [11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}, co‐segregated with type 1 diabetes. Notably, type 1 diabetes was seen in cases 1 and 2, but not in the father or the older siblings of case 1, although *HLA* risk alleles were shared by all of these individuals. Whereas 23 other nucleotide substitutions were also linked to the disease phenotype of this family, there were no data supporting an association between these substitutions and diabetes. In fact, many of the 23 substitutions were of unknown pathogenicity, or resided within genes that underlie human disorders other than diabetes. Although cases 1 and 2 carried a p.I228T substitution (rs143186590) in *GAD2* encoding a major autoantigen of type 1 diabetes, a relatively high frequency of *GAD2* p.I228T in the general population argued against the pathogenicity of this mutation. Johnson *et al*.[18](#jdi12586-bib-0018){ref-type="ref"} suggested that genetic variations in *GAD2* are unlikely to underlie type 1 diabetes. Actually, *GAD2* variations have been associated with obesity and anxiety disorders, rather than type 1 diabetes[19](#jdi12586-bib-0019){ref-type="ref"}, [20](#jdi12586-bib-0020){ref-type="ref"}. Mutations in known diabetes‐causative genes, including *INS*,*PTPN22*,*IL2RA* and *CTLA4* were excluded in family A. Furthermore, although several submicroscopic deletions in the genome have been associated with type 1 diabetes[21](#jdi12586-bib-0021){ref-type="ref"}, such defects were absent in case 1. Subsequently, we carried out *CD101* mutation screening of 127 sporadic patients with type 1 diabetes and identified additional missense substitutions. The p.V863L, p.V678L and p.T944R substitutions in *CD101* were absent or extremely rare in the general population, and were scored as possibly or probably damaging. Furthermore, the three substitutions were well‐conserved among most placental mammals. Collectively, the present findings, in conjunction with prior observations that CD101 plays a significant role in T cell regulation[6](#jdi12586-bib-0006){ref-type="ref"}, [7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}, [9](#jdi12586-bib-0009){ref-type="ref"}, [10](#jdi12586-bib-0010){ref-type="ref"}, [11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}, [13](#jdi12586-bib-0013){ref-type="ref"}, [14](#jdi12586-bib-0014){ref-type="ref"}, [15](#jdi12586-bib-0015){ref-type="ref"}, [16](#jdi12586-bib-0016){ref-type="ref"}, [22](#jdi12586-bib-0022){ref-type="ref"}, [23](#jdi12586-bib-0023){ref-type="ref"}, imply an association between *CD101* mutations and type 1 diabetes. *CD101* mutations might increase genetic predisposition to diabetes only in individuals at risk of the disease, because cases 1--4 invariably carried one or more of the *HLA* risk alleles. While the mother of case 2 was free from the disease despite having the same *CD101* substitution as cases 1 and 2, this normal phenotype might reflect the presence of the protective *DQB1\*03:01* allele. Considering the small number of participants in the present study, our findings need to be validated in future studies.

Fluorescence‐activated cell sorting analysis detected CD101 expression on hematopoietic cells in both control individuals and mutation‐positive patients. The percentage of CD101‐positive cells among monocytes, neutrophils and myeloid DCs was somewhat lower in cases 1, 2 and 4 compared with that in five control individuals. The underlying mechanism of the reduced *CD101* expression in these cases remains unknown. Actually, the signal peptide and the transmembrane domain are not affected by the p.V678L or p.T944R substitutions. Furthermore, it is unclear whether these minor differences in the expression levels are of clinical significance. We cannot exclude the possibility that *CD101* mutations identified in the present study are functionally neutral variants. Nevertheless, altered CD101 expression has been associated with various autoimmune disorders. Jovanovic *et al*.[16](#jdi12586-bib-0016){ref-type="ref"} showed that the fraction of CD101‐positive cells among the CD8+ T cell population was reduced in patients with rheumatoid arthritis. Ǻkesson *et al*.[23](#jdi12586-bib-0023){ref-type="ref"} found that CD101 expression in regulatory T cells was moderately increased in children with celiac disease. In addition, reduced surface expression of murine CD101 was associated with the risk of infection‐induced liver autoimmunity[22](#jdi12586-bib-0022){ref-type="ref"}. Altered expression of CD101 on DCs could influence the progression of pancreatic insulitis, because DCs are known to play a critical role in the recruitment of lymphocytes in insulitis of the NOD mouse[24](#jdi12586-bib-0024){ref-type="ref"}. Further studies, such as viral vector‐mediated transduction of the mutant *CD101* to immune cells, will clarify the functional consequences of the p.V678L, p.V863L and p.T944R substitutions.

Previous GWAS did not suggest any association between *CD101* and diabetes. This can be explained by the rarity of *CD101* substitutions in the general population. It is known that disease‐associated variants with an allele frequency of less than 0.5% in the general population are barely detectable by GWAS, unless the variants underlie monogenic Mendelian disorders[5](#jdi12586-bib-0005){ref-type="ref"}. As we identified *CD101* substitutions in just two of the 127 sporadic patients, such substitutions appear to be rare, even in patient cohorts. The present results show that next‐generation sequencing of familial cases is useful for identifying rare risk variants that have been missed by GWAS.

In conclusion, we identified rare *CD101* mutations in familial and sporadic cases of type 1 diabetes. The present findings, in conjunction with the results of previous studies[6](#jdi12586-bib-0006){ref-type="ref"}, [7](#jdi12586-bib-0007){ref-type="ref"}, [8](#jdi12586-bib-0008){ref-type="ref"}, [9](#jdi12586-bib-0009){ref-type="ref"}, [10](#jdi12586-bib-0010){ref-type="ref"}, [11](#jdi12586-bib-0011){ref-type="ref"}, [12](#jdi12586-bib-0012){ref-type="ref"}, [13](#jdi12586-bib-0013){ref-type="ref"}, [14](#jdi12586-bib-0014){ref-type="ref"}, [15](#jdi12586-bib-0015){ref-type="ref"}, [16](#jdi12586-bib-0016){ref-type="ref"}, [22](#jdi12586-bib-0022){ref-type="ref"}, [23](#jdi12586-bib-0023){ref-type="ref"}, [24](#jdi12586-bib-0024){ref-type="ref"}, raise the possibility that *CD101* is a susceptibility gene for type 1 diabetes.
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